1st Feb 2007 07:00
Tepnel Life Sciences PLC01 February 2007 FOR IMMEDIATE RELEASE Tepnel Life Sciences plc ('Tepnel' or 'the Company') Tepnel grants exclusive license for Solid Phase Amplification (SPA) technology to US-based company Manchester, U.K., 1 February January 2007 Tepnel Life Sciences PLC (AIM: TED),the international Molecular Diagnostics and Research Products & Services group,announced today that it has granted exclusive licensing rights to its SolidPhase Amplification (SPA) technology for use in the field of non-bead basedamplification prior to nucleic acid sequencing to a US-based company. The SPAtechnology, which was developed by Tepnel's Research Products and ServicesDivision, can be used in DNA sequencing systems. Tepnel will receive an up front payment as well as ongoing annual royalties anda shared split on sub-licensing monies. Commenting on the licensing agreement, Ben Matzilevich, Tepnel CEO said, "Tepnelis pleased to licence certain aspects of our nucleic acid amplificationtechnology. This technology has the potential to increase the capacity of DNAsequencing automated systems. This agreement highlights the continued success ofour Research Products and Services business and the efforts of our researchstaff." -End- For Further Information: Tepnel Life Sciences plcBen Matzilevich, CEOTel: 0161 946 2200 Capital MS&LMary Clark or Halina KukulaTel: +44 20 7307 5330Email: [email protected] Notes to Editors About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. TLS provides testkits, reagents and services to two highly synergistic markets, these beingMolecular Diagnostics and Biomedical Research. The company's strategy has beento identify high growth niche opportunities within these multi-billion poundmarkets. TLS focuses on these niche opportunities with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. SPA Technology The traditional approach to gene analysis relies on using the polymerase chainreaction (PCR) and involves the hybridisation of labelled probes tofree-floating DNA targets that are passively absorbed to solid supports such asnitrocellulose. SPA technology differs from this by instead using surface-boundDNA primers to limit amplification to two-dimensional surfaces. This enablesmore rapid amplification of the DNA targets and is particularly valuable to theDNA microchip industry for the large scale assays of genetic material. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L